Positron Emission Tomography-Adapted Therapy in Bulky Stage I/II Classic Hodgkin Lymphoma: CALGB 50801 (Alliance).

Ann Steward LaCasce Travis Dockter Amy S Ruppert Lale Kostakoglu Heiko Schöder Eric D Hsi Jeffrey A Bogart Bruce D ChesonNina Wagner-JohnstonJeremy S Abramson Kristie A BlumJohn P LeonardNancy L Bartlett

Published in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2022)

Our study of PET-adapted therapy in bulky stage I/II cHL met its primary goal and was associated with an excellent 3-year PFS rate of 92.3% in all patients, with the majority being spared radiotherapy and exposure to intensified chemotherapy.

Keyphrases

positron emission tomography
hodgkin lymphoma
computed tomography
pet ct
pet imaging
locally advanced
radiation therapy
spinal cord injury
rectal cancer
cell therapy